Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Al Rashid, S. T.
Right arrow Articles by Bristow, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Al Rashid, S. T.
Right arrow Articles by Bristow, R. G.
[Cancer Research 65, 10810-10821, December 1, 2005]
© 2005 American Association for Cancer Research


Cell and Tumor Biology

Evidence for the Direct Binding of Phosphorylated p53 to Sites of DNA Breaks In vivo

Shahnaz T. Al Rashid1,2, Graham Dellaire4, Andrew Cuddihy1, Farid Jalali1, Mita Vaid5, Carla Coackley1, Melvyn Folkard5, Yang Xu6, Benjamin P.C. Chen7, David J. Chen7, Lothar Lilge1,2, Kevin M. Prise5, David P. Bazett Jones4 and Robert G. Bristow1,2,3

1 Ontario Cancer Institute Princess Margaret Hospital, University Health Network; Departments of 2 Medical Biophysics and 3 Radiation Oncology, University of Toronto; 4 Programme in Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada; 5 Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom; 6 Division of Biological Sciences, University of California, San Diego, La Jolla, California; and 7 Division of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas

Requests for reprints: Robert G. Bristow, Experimental Therapeutics, Ontario Cancer Institute/Princess Margaret Hospital, Room 5-923, 610 University Avenue, Toronto, Ontario, Canada M5G2M9. Phone: 416-946-2129; Fax: 416-946-4586; E-mail: rob.bristow{at}rmp.uhn.on.ca.

Despite a clear link between ataxia-telangiectasia mutated (ATM)–dependent phosphorylation of p53 and cell cycle checkpoint control, the intracellular biology and subcellular localization of p53 phosphoforms during the initial sensing of DNA damage is poorly understood. Using G0-G1 confluent primary human diploid fibroblast cultures, we show that endogenous p53, phosphorylated at Ser15 (p53Ser15), accumulates as discrete, dose-dependent and chromatin-bound foci within 30 minutes following induction of DNA breaks or DNA base damage. This biologically distinct subpool of p53Ser15 is ATM dependent and resistant to 26S-proteasomal degradation. p53Ser15 colocalizes and coimmunoprecipitates with {gamma}-H2AX with kinetics similar to that of biochemical DNA double-strand break (DNA-dsb) rejoining. Subnuclear microbeam irradiation studies confirm p53Ser15 is recruited to sites of DNA damage containing {gamma}-H2AX, ATMSer1981, and DNA-PKcsThr2609 in vivo. Furthermore, studies using isogenic human and murine cells, which express Ser15 or Ser18 phosphomutant proteins, respectively, show defective nuclear foci formation, decreased induction of p21WAF, decreased {gamma}-H2AX association, and altered DNA-dsb kinetics following DNA damage. Our results suggest a unique biology for this p53 phosphoform in the initial steps of DNA damage signaling and implicates ATM-p53 chromatin-based interactions as mediators of cell cycle checkpoint control and DNA repair to prevent carcinogenesis.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
S. Leng, C. A. Stidley, A. M. Bernauer, M. A. Picchi, X. Sheng, M. A. Frasco, D. Van Den Berg, F. D. Gilliland, R. E. Crowell, and S. A. Belinsky
Haplotypes of DNMT1 and DNMT3B are associated with mutagen sensitivity induced by benzo[a]pyrene diol epoxide among smokers
Carcinogenesis, July 1, 2008; 29(7): 1380 - 1385.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. R. Cuddihy, F. Jalali, C. Coackley, and R. G. Bristow
WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells
Mol. Cancer Ther., April 1, 2008; 7(4): 980 - 992.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Malmlof, G. Paajarvi, J. Hogberg, and U. Stenius
Mdm2 as a Sensitive and Mechanistically Informative Marker for Genotoxicity Induced by Benzo[a]pyrene and Dibenzo[a,l]pyrene
Toxicol. Sci., April 1, 2008; 102(2): 232 - 240.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
F. Rodier, J. Campisi, and D. Bhaumik
Two faces of p53: aging and tumor suppression
Nucleic Acids Res., December 3, 2007; 35(22): 7475 - 7484.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.